Ruxience, a monoclonal antibody (mAb), has been approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Ruxience works
The post Pfizer gets FDA nod for biosimilar to Roche’s cancer drug Rituxan appeared first on Pharmaceutical Business review.
Original Article: Pfizer gets FDA nod for biosimilar to Roche’s cancer drug Rituxan